Kemin - Inspired Molecular Solutions

Pharmaceuticals | Products

Recently Clostridium difficile associated diarrhea (CDAD) has been blamed on an emerging, lethal strain of Clostridium difficile.

  • Antibiotic associated diarrhea (AAD), CDAD often stems from antibiotics-related pathogen overgrowth in the gastrointestinal tract.
  • Travel, stress and other factors can disrupt good digestive and gastrointestinal health.
  • Deadly hospital outbreaks of Clostridium difficile associated diarrhea (CDAD) have been tied to this emerging strain of Clostridium difficile.

 

In response, Kemin has developed a proprietary product, Bacillus subtilis Strain PB6.

Bacillus subtilis Strain PB6, when marketed as a safe probiotic under the brand name Anaban:

  • Intended to promote the growth and activity of health-stimulating bacteria in the intestinal tract.
  • Improves gastrointestinal and digestive health issues that may be associated with antibiotic usage, travel and stress.
  • At a higher dosage, Bacillus subtilis Strain PB6 is intended for market under the brand name Inflammaban.

 

Inflammaban is currently under research and development for indications that include:

  • Ulcerative colitis
  • Crohn's disease
  • Irritable bowel syndrome
  • AAD
  • CDAD

 

Anaban® Brand Probiotic

A safe probiotic for gastrointestinal and digestive health in a lower dose.

 

Inflammaban™ Brand Probiotic

Targets ulcerative colitis, Crohn's disease and irritable bowel syndrome, as well as AAD and CDAD.

 

These statements have not been evaluated by the Food and Drug Administration. This product is not available in all geographies and is not intended to diagnose, treat, cure or prevent any disease.